Biophytis AGM meeting will take place on May 11, 2020 without the physical
presence of its shareholders
Preparatory & all required documents for shareholders' votes are available on
Paris (France), Cambridge (Etats-Unis), April 30 , 2020, 7:00 p.m. CEST -
BIOPHYTIS (Euronext Growth Paris: ALBPS), a clinical-stage biotechnology
company specialized in the development of drug candidates for treatment of aged
related diseases, especially neuromuscular diseases, will hold its Annual
General Meeting (AGM) on May 11th 2020 at 2 p.m. at the offices of Reed Smith
LLP, 112 avenue Kléber, 75016 Paris. As a result of restrictions placed on the
movement and gatherings of persons due to the COVID-19 pandemic, the Company's
Combined General Meeting will be held behind closed doors without the physical
presence of its shareholders, in accordance with the provisions of Article 4 of
Order no. 2020-321 of March 25th, 2020.
The notice of meeting, comprising the agenda and the draft resolutions was
published in the French official legal bulletin Bulletin des Annonces Légales
Obligatoires (BALO) n° 42. These notices include information on how to attend
and vote at the General Meeting, as well as the vote bulletin. All these
documents are also available on its website.
Shareholders are strongly encouraged to vote in advance of the shareholder
meeting by mail, by appointing the Chairman of the meeting as your proxy or via
the secure online platform VOTEACCESS.
On account of the possible effect of the Covid-19 pandemic on postal delivery
times, it is recommended to return your voting forms as soon as practicable.
Please note that the voting forms should be submitted no later than :
- For postal votes, the statutory deadlines apply :
o May 7 (4-day deadline before the Meeting) for issuing instructions to the
o May 8 (3-day deadline before the Meeting) for appointing the proxy
- VOTEACCESS :
o May 10 at 3 p.m. CEST
Biophytis SA is a clinical-stage biotechnology company specialized in the
development of drug candidates to slow down degenerative processes and improve
functional abilities in patients with age- related diseases, especially
Sarconeos (BIO101), our leading drug candidate, is a small molecule,
administered orally, currently in clinical Phase 2b in sarcopenia (SARA-INT) in
the United States and Europe. A pediatric formulation of BIO101 is being
developed for the treatment of Duchenne Muscular Dystrophy (DMD). The company
plans to start the clinical development in H2 2020.
Sarconeos (BIO101) will also be developed as a treatment for Covid-19
(Coronavirus) for which the company has filed a clinical trial application with
the French Regulatory Authority (ANSM).
The company is based in Paris, France, and Cambridge, Massachusetts. The
company's common shares are listed on the Euronext Growth Paris market (Ticker:
ALBPS -ISIN: FR0012816825). For more information www.biophytis.com.
This press release contains forward-looking statements. While the Company
considers its projections to be based on reasonable assumptions, these
forward-looking statements may be called into question by a number of hazards
and uncertainties, so that actual results may differ materially from those
anticipated in such forward- looking statements. For a description of the risks
and uncertainties likely to affect the results, BIOPHYTIS' financial position,
performance or achievements and thus cause a change from the forward-looking
statements, please refer to the "Risk Factors" section of the Company's 2018
Annual Report available on BIOPHYTIS website ( www.biophytis.com).
This press release, and the information contained in it, does not constitute an
offer to sell or subscribe, nor the solicitation of a purchase or subscription
order, of BIOPHYTIS shares in any country. The elements contained in this
communication may contain forward-looking information involving risks and
uncertainties. The Company's actual achievements may differ materially from
those anticipated in this information due to different risk and uncertainty
factors. This press release was written in French and English; If there is a
difference between the texts, the French version will prevail.
Biophytis Contact for Investor Relations
Evelyne Nguyen, CFO